Christopher Cann

Christopher Cann

Auto-generated profile, based on publicly available information

Christopher Cann

Fox Chase Cancer Center, Philadelphia, PA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
LSLavanya Sivapalan
Lavanya Sivapalan
WIWade T. Iams
Wade T. Iams
ZBZineb Belcaid
Zineb Belcaid
SSSusan C. Scott
Susan C. Scott
NNNoushin Niknafs
Noushin Niknafs
VAValsamo Anagnostou
Valsamo Anagnostou
Purpose: Patients with small-cell lung cancer (SCLC) have an exceptionally poor prognosis, calling for improved real-time noninvasive biomarkers of therapeutic response. Experimental Design: We performed targeted error-correction sequencing on 171 serial plasmas and matched white blood cell (WBC) DNA from 33 patients with metastatic SCLC who received treatment with chemotherapy (n = 16) or immunotherapy-containing (n = 17) regimens. Tumor-derived sequence alterations and plasma aneuploidy were evaluated serially and combined to assess changes in total cell-free tumor load (cfTL). Longitudinal dynamic changes in cfTL were monitored to determine circulating cell-free tumor DNA (ctDNA) molecular response during therapy. Results: Combined tiered analyses of tumor-derived sequence alterations and plasma aneuploidy allowed for the assessment of ctDNA molecular response in all patients. Patients classified as molecular responders (n = 9) displayed sustained elimination of cfTL to undetectable levels. For 14 patients, we observed initial molecular responses, followed by ctDNA recrudescence. A subset of patients (n = 10) displayed a clear pattern of molecular progression, with persistence of cfTL across all time points. Molecular responses captured the therapeutic effect and long-term clinical outcomes in a more accurate and rapid manner compared with radiographic imaging. Patients with sustained molecular responses had longer overall (log-rank P = 0.0006) and progression-free (log-rank P < 0.0001) survival, with molecular responses detected on average 4 weeks earlier than imaging. Conclusions: ctDNA analyses provide a precise approach for the assessment of early on-therapy molecular responses and have important implications for the management of patients with SCLC, including the development of improved strategies for real-time tumor burden monitoring. See related commentary by Pellini and Chaudhuri, p. 2176

8 May 2025 in The Oncologist
Verified
Journal Article
Open access
CCChristopher G. Cann
Christopher G. Cann
MLMichael LaPelusa
Michael LaPelusa
SCSarah Cimino
Sarah Cimino
VCVictoria Cancelliere
Victoria Cancelliere
EDElizabeth Dow-Hillgartner
Elizabeth Dow-Hillgartner
CECathy Eng
Cathy Eng
Background: Trifluridine-tipiracil (TAS-102) is approved as monotherapy and in combination with bevacizumab for refractory unresectable metastatic colorectal cancer (mCRC). The recommended dose is 35 mg/m2 twice daily on days 1-5 and days 8-12 of 28-day cycles commonly resulting in grade 3-4 neutropenia, dose delays/reductions, and requiring GCSF support. To maintain efficacy and reduce toxicity, we analyzed a biweekly dosing schedule (days 1-5 and days 15-19 q28 days). Patients and Methods: A retrospective analysis was performed in patients with mCRC and appendiceal cancer who completed >12 days of TAS-102 therapy and underwent surveillance imaging every 8-12 weeks. ECOG performance status (PS), prior lines of therapy, use of bevacizumab, CTCAE grade of treatment-related myelotoxicity, dose reductions/delays, and use of GCSF were assessed. Among patients with mCRC, survival analyses were performed. Results: 61 patients met inclusion criteria, with mCRC:appendiceal CA ratio of 56:5. Median ECOG PS = 1; median number of prior therapies = 3; Reduction in grade ≥3 neutropenia (16.3%, 1 patient with grade 4) and grade ≥3 anemia (8.2%) relative to the historic controls of the RECOURSE and SUNLIGHT trials. No neutropenic fever was noted; GCSF was not required. Eight patients required a dose delay. In the mCRC patients, the median progression-free survival (PFS) was 4.2 months, with a median overall survival (OS) of 9.2 months. Conclusions: Biweekly dosing of TAS-102 demonstrated a reduction in myelosuppression, with similar PFS and OS. With an improved toxicity profile, this alternative dosing schedule may potentially broaden the utilization of TAS-102 in patients with borderline PS and provide a favorable option for future combination studies.

1 August 2024 in Journal of Gastrointestinal Oncology
Verified
Journal Article
Open access
PDF file
CCChristopher G. Cann
Christopher G. Cann
EDEfrat Dotan
Efrat Dotan
Transverse colon cancer: a call for focused research in an understudied heterogenous disease

21 March 2024 in ESMO Gastrointestinal Oncology
Verified
Journal Article
Open access
CCChristopher G. Cann
Christopher G. Cann
CSC. Shen
C. Shen
MLMichael LaPelusa
Michael LaPelusa
DCD. Cardin
D. Cardin
JBJ. Berlin
J. Berlin
CEC. Eng
C. Eng
Nearly one-third of patients with newly diagnosed pancreatic cancer present with locally advanced disease (LAPC), with 25% eligible for surgical resection, lending to a poor 5-year overall survival of 16.2%. Given the significant morbidity and mortality associated with LAPC, timely integration of palliative and supportive care (SC) into the treatment care plan is vital. The purpose of this study was to investigate the utilization of SC in patients with LAPC and identify the demographic and socioeconomic factors that influence its application. A retrospective database analysis of the National Cancer Database (NCDB) was carried out. Data regarding patients diagnosed with stage II-III LAPC between 2004 and 2018 were used. Analyses included tumor characteristics, demographics, socioeconomic parameters, and trends in utilization of SC. A total of 111 964 patients were included [stage II (72.3%); stage III (27.6%)]. Only 7.72% received SC despite 67% of patients receiving cancer-directed treatment at an academic or integrated network cancer program, 84% living in or near a metro area, and 60% living ≤20 miles of their primary treatment center. Rates of SC utilization remained <8% and <12% in stage II and III disease, respectively, throughout the two decades. SC has been underutilized in the LAPC population over the past two decades, despite the increase in data supporting early integration of palliative care and the potential sociodemographic areas of unmet need. Future work should focus on evaluating practice patterns across cancer centers and the potential positive impact of early SC integration on both survival and quality-of-life outcomes for patients with LAPC.

3 July 2025 in Cancer Discovery
Verified
Journal Article
Closed access
CCChristopher G. Cann
Christopher G. Cann
CECathy Eng
Cathy Eng
Summary: Shiels and colleagues analyzed the incidence data from the US Cancer Statistics Database and death certificate data from the National Center for Health Statistics to depict the incidence and mortality trends across both early-onset and average age–onset patients diagnosed with cancer over the past decade, with the objective to refine the understanding of etiologic factors and exposures that may be driving the observed increase in early-onset cancer. Their approach revealed that the majority of early-onset cancer diagnoses occurred in females; there was a significant increase in multiple cancers, most significantly in breast cancer and colon cancer; and although mortality did not increase across the entire early-onset population, mortality rates increased within colorectal, uterine, and testicular cancers. See related article by Shiels et al., p. 1363 .

1 December 2025 in Annals of Internal Medicine
Verified
Journal Article
Closed access
CCChristopher G. Cann
Christopher G. Cann
EDEfrat Dotan
Efrat Dotan